Additive effects of fecal microbiota transplantation and infliximab on gut microbiome and metabolome in refractory inflammatory bowel disease patients | Synapse
March 25, 2026Open Access
Additive effects of fecal microbiota transplantation and infliximab on gut microbiome and metabolome in refractory inflammatory bowel disease patients
Key Points
The research aims to investigate how fecal microbiota transplantation and infliximab together affect the gut microbiome and metabolome in patients with refractory inflammatory bowel disease.
Registered as ClinicalTrials.gov NCT07149441
Evaluated effects on gut microbiome and metabolome
Included patients with refractory inflammatory bowel disease
Combined treatment improved gut microbiome diversity